Loading...

Albireo Pharma, Inc.

ALBO•NASDAQ
Healthcare
Biotechnology
$44.15
$0.00(0.00%)

Albireo Pharma, Inc. (ALBO) Stock Overview

Explore Albireo Pharma, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 62.7/100

Key Financials

Market Cap915.9M
P/E Ratio-5.61
EPS (TTM)$-6.66
ROE-0.85%

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$18.91

ALBO Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Albireo Pharma, Inc. (ALBO) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $18.91.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -5.61 and a market capitalization of 915.9M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for ALBOStats details for ALBO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ALBOAnalyst Recommendations details for ALBO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

CEO

Mr. Ronald H. W. Cooper

Employees

130

Headquarters

10 Post Office Square, Boston, MA

Founded

2007

Frequently Asked Questions

;